Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + POF vs Tislelizumab + FOLFOX in Gastric Cancer
NCT06793917Phase 3Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Jun 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Fujian Medical University Cancer Hospital. Primary endpoint: Progression-Free Survival at 4 years. Started Jun 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06793917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06793917.